Equities analysts forecast that Syneos Health Inc (NASDAQ:SYNH) will post earnings of $1.01 per share for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Syneos Health’s earnings. The highest EPS estimate is $1.03 and the lowest is $0.99. Syneos Health reported earnings of $0.95 per share during the same quarter last year, which would suggest a positive year over year growth rate of 6.3%. The firm is expected to issue its next earnings report on Monday, March 16th.

On average, analysts expect that Syneos Health will report full-year earnings of $3.21 per share for the current financial year, with EPS estimates ranging from $3.19 to $3.23. For the next fiscal year, analysts forecast that the business will report earnings of $3.63 per share, with EPS estimates ranging from $3.60 to $3.68. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Syneos Health.

Syneos Health (NASDAQ:SYNH) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.05. Syneos Health had a return on equity of 10.13% and a net margin of 1.86%. The business had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same period last year, the business earned $0.75 EPS. The business’s revenue was up 5.6% on a year-over-year basis.

Several equities analysts have weighed in on SYNH shares. ValuEngine upgraded Syneos Health from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Credit Suisse Group raised their price objective on Syneos Health from $56.00 to $58.00 and gave the company an “outperform” rating in a research note on Friday, August 23rd. Jefferies Financial Group raised their price objective on Syneos Health from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. UBS Group raised their price objective on Syneos Health from $53.50 to $57.00 and gave the company a “neutral” rating in a research note on Thursday, August 29th. Finally, SunTrust Banks lifted their target price on Syneos Health to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Syneos Health has a consensus rating of “Buy” and a consensus price target of $59.50.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Financial Gravity Wealth Inc. bought a new stake in shares of Syneos Health during the 2nd quarter worth $29,000. Quest Capital Management Inc. ADV purchased a new stake in Syneos Health in the 3rd quarter worth about $99,000. CSat Investment Advisory L.P. purchased a new stake in Syneos Health in the 2nd quarter worth about $136,000. Convergence Investment Partners LLC purchased a new stake in Syneos Health in the 3rd quarter worth about $147,000. Finally, Tower Research Capital LLC TRC increased its holdings in Syneos Health by 48.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,272 shares of the company’s stock worth $167,000 after acquiring an additional 1,073 shares during the last quarter.

NASDAQ:SYNH traded up $0.69 during trading hours on Thursday, hitting $51.66. 234,374 shares of the company traded hands, compared to its average volume of 566,357. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 1.02. The firm’s 50-day simple moving average is $52.18 and its 200-day simple moving average is $49.67. Syneos Health has a one year low of $36.26 and a one year high of $56.34. The company has a market cap of $5.33 billion, a PE ratio of 19.72, a PEG ratio of 1.74 and a beta of 1.49.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Recommended Story: What is a good rate of return for a mutual fund?

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.